Patients with clopidogrel loss-of-function gene patterns who received a stent for acute myocardial infarction saw a sharp decline in ischemic events in one year as a result of genotype-guided antiplatelet therapy, according to the GIANT trial. The trial included 316 patients with the LOF genotype, 86% of whom had their prescribed antiplatelet therapy adjusted in response to assay results. The one-year composite risk of death, heart attack or stent thrombosis was similar to that of patients who didn't have the high-risk genotype, according to the study, while the end point composite was five times higher for those whose therapy was not changed based on the findings. SCAI fellow Dr. Cindy Grines called the findings "amazing."
Published in Brief: